Genufood Energy Enzymes Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Lai Wen Piao, was filed 10 Aug 2021.
Genufood Energy Enzymes Corp.: what insiders have been doing
Genufood Energy Enzymes Corp., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at Genufood Energy Enzymes Corp. has published a filing in the past twelve months. The most recent one dates from 10 August 2021.
Since 2021, the database holds 6 purchases and no sales by insiders of the company.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -31.1%Entry US$0.05 · Close at T+365 US$0.03
- -31.1%Entry US$0.05 · Close at T+365 US$0.03
- -31.1%Entry US$0.05 · Close at T+365 US$0.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended September 2023 · cache
- 3,000,000 shares@ US$0.01Common StockSEC:0001213900-21-041293:1Canonical exit: 13 Oct 2021 (T+90)
- 4,000,000 shares@ US$0.01100.0% of flowCommon StockSEC:0001213900-21-041263:0Canonical exit: 13 Sept 2021 (T+90)
- 1,000,000 shares@ US$0.01100.0% of flowCommon StockSEC:0001213900-21-041264:0Canonical exit: 13 Oct 2021 (T+90)
- 8,000,000 shares@ US$0.01100.0% of flowCommon StockSEC:0001213900-21-041293:0Canonical exit: 13 Sept 2021 (T+90)
- 420,000 shares@ US$0.05Common StockSEC:0001213900-21-023482:0
- 1,800,000 shares@ US$0.01Common StockSEC:0001213900-21-023482:1
- 201,889 shares@ US$0.05Common StockSEC:0001213900-21-023485:0
- 1,200,000 shares@ US$0.01Common StockSEC:0001213900-21-023485:1
- 1,500,000 shares@ US$0.01Common StockSEC:0001213900-21-023612:0
- 30,000,000 shares@ US$0.01Common StockSEC:0001213900-21-017409:0Canonical exit: 15 Mar 2021 (T+90)
- 6,000,000 shares@ US$0.01Common StockSEC:0001213900-21-017411:0Canonical exit: 15 Mar 2021 (T+90)
11 of 11 declarations
About Genufood Energy Enzymes Corp.
Genufood Energy Enzymes Corp. is a U.S.-based micro-cap issuer in the American listed-equity universe, referenced in SEC filings and described here for investors following NYSE/NASDAQ-style U.S. market exposure. The company is incorporated in Nevada and its principal business address in recent SEC disclosures is in Arcadia, California, United States. Genufood was formed on June 21, 2010 as a start-up focused on promoting, marketing, distributing, and exporting enzyme-related products for human and animal consumption. Early SEC disclosures framed the business as export-oriented, initially targeting Taiwan and then broader Asian markets including China, Hong Kong, Macau, Thailand, Malaysia, Singapore, and Sri Lanka.
From a business-model perspective, Genufood has historically positioned itself more as a marketer and distributor than as a fully integrated manufacturer. Its early filings referenced enzyme products marketed under trademarks such as ProCellax and ProAnilax, with contract manufacturing arrangements involving OEM partners in the United States and Taiwan. That structure suggests an asset-light model with reliance on third-party manufacturing, distribution relationships, and external capital. In practice, the SEC record indicates a company with limited operating history and modest scale, which makes its equity story highly dependent on execution, financing access, and the ability to commercialize niche products.
Read moreShow less
In competitive terms, Genufood is not a scaled pharmaceutical or large nutraceutical platform. Its market position appears narrow and speculative, but it may appeal to investors who are looking for optionality around enzyme-based health and wellness products. The challenge is that the company’s public record shows persistent financial constraints and a need for ongoing capital, so the investment case remains high risk. More recent public disclosures also suggest a willingness to diversify beyond the original enzyme thesis. In 2022, the company announced agreements to install electric-vehicle charging stations at selected sites, indicating an exploratory move into a different revenue stream and a broader corporate repositioning.
Recent company-specific developments have been more about governance and financing than about large-scale operating momentum. In July 2023, Genufood announced the resignation of its CFO and the appointment of Kuang Ming (James) Tsai as the new CFO. The company stated that his responsibilities would include financial reporting and fundraising, which underscores the importance of capital formation for the business. For investors, that is a meaningful signal: the company remains in a rebuilding or restructuring phase, with management emphasizing financing, reporting discipline, and potential strategic adjustment. Overall, Genufood Energy Enzymes Corp. remains a very small U.S. issuer with a historical enzyme focus, an Arcadia, California operating footprint, Nevada incorporation, and a profile that should be read as speculative and financing-sensitive rather than as a mature operating platform.
